Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSCG | ISIN: US00510M1045 | Ticker-Symbol: 3ZO
Tradegate
28.03.25
17:36 Uhr
0,392 Euro
+0,011
+2,89 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACURX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ACURX PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3760,39112:11
0,3750,39210:10

Aktuelle News zur ACURX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.03.Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update226STATEN ISLAND, N.Y., March 18, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical...
► Artikel lesen
18.03.Acurx Pharmaceuticals, Inc Full Year Loss Narrows2
18.03.Acurx Pharmaceuticals, Inc. - 8-K, Current Report2
ACURX PHARMACEUTICALS Aktie jetzt für 0€ handeln
18.03.Acurx Pharmaceuticals GAAP EPS of -$0.874
17.03.Acurx Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
17.03.Acurx Pharmaceuticals, Inc. - 10-K, Annual Report2
14.03.New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP237NEW YORK CITY, NY / ACCESS Newswire / March 14, 2025 / The highly anticipated Visionaries Series from New to The Street and Sight & Sound premieres tomorrow on Bloomberg at 6:30 PM EST as sponsored...
► Artikel lesen
10.03.Acurx Pharmaceuticals, Inc. - 8-K, Current Report3
07.03.Why Acurx Pharmaceuticals (ACXP) Shares Are Down 30%4
07.03.Acurx Pharmaceuticals stock sinks on $1.1M direct offering4
03.03.Acurx Pharmaceuticals, Inc.: Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics211First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse modelChanges in alpha and beta microbiome...
► Artikel lesen
26.02.Acurx Pharmaceuticals, Inc. - 8-K, Current Report2
24.02.Acurx Pharmaceuticals Advances To Phase 3 Trials For C. Difficile Infection, Stock Down3
24.02.Acurx's ibezapolstat shows selective bacterial targeting4
24.02.Acurx Pharmaceuticals, Inc.: Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI235 Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target DNA pol IIIC is conserved across...
► Artikel lesen
19.02.Acurx Pharmaceuticals sichert sich japanisches Patent für Antibiotika2
19.02.Acurx Pharmaceuticals secures Japanese patent for antibiotics5
31.01.Acurx Pharmaceuticals files for secondary offering5
31.01.Acurx Pharmaceuticals, Inc. - S-1, General form for registration of securities1
07.01.Acurx Pharmaceuticals, Inc. - 8-K, Current Report1
Seite:  Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1